Peter Hersey

Peter Hersey

UNVERIFIED PROFILE

Are you Peter Hersey?   Register this Author

Register author
Peter Hersey

Peter Hersey

Publications by authors named "Peter Hersey"

Are you Peter Hersey?   Register this Author

100Publications

10520Reads

40Profile Views

Shedding light on dabrafenib-induced fevers in patients with melanoma.

Lancet Oncol 2019 Dec;20(12):1637-1638

Melanoma Oncology Group, Centenary Institute, University of Sydney, Sydney 2050, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(19)30681-3DOI Listing
December 2019

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy.

Trends Immunol 2019 Apr 7;40(4):328-344. Epub 2019 Mar 7.

Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia; Senior author. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2019.02.004DOI Listing
April 2019

Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma.

J Clin Oncol 2018 06 28;36(17):1668-1674. Epub 2017 Dec 28.

Caroline Robert, Gustave Roussy Cancer Campus and Paris Sud University, Villejuif Paris-Sud, France; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Adil Daud, University of California, San Francisco, San Francisco, CA; Jedd D. Wolchok, Ludwig Center, Memorial Sloan Kettering Cancer Center, New York, NY; Anthony M. Joshua, The Princess Margaret Cancer Centre, Toronto, Ontario, Canada; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H Lee Moffitt Cancer Center, Tampa; Richard W. Joseph, Mayo Clinic Cancer Center-Florida, Jacksonville, FL; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, UPMC Hillman Cancer Center, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; Melanoma Institute Australia, Wollstonecraft; and Macquarie University, MQ Health, Health Sciences Centre; Peter Hersey, University of Sydney, Sydney, New South Wales, Australia; Jin Zhang, James Anderson, Scott J. Diede, and Scot Ebbinghaus, Merck & Co., Inc., Kenilworth, NJ; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2017.75.6270
Publisher Site
http://dx.doi.org/10.1200/JCO.2017.75.6270DOI Listing
June 2018

Marked Global DNA Hypomethylation Is Associated with Constitutive PD-L1 Expression in Melanoma.

iScience 2018 Jun 28;4:312-325. Epub 2018 Jun 28.

Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Royal Prince Alfred Hospital, Missenden Road, Camperdown, NSW 2050, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.isci.2018.05.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6147024PMC
June 2018

Epigenetic modulation in cancer immunotherapy.

Curr Opin Pharmacol 2017 08 10;35:48-56. Epub 2017 Jun 10.

Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Camperdown, NSW, Australia; Melanoma Institute Australia, Crow's Nest 2065, Sydney, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coph.2017.05.006DOI Listing
August 2017

Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.

N Engl J Med 2017 06;376(23):2211-2222

From the John Wayne Cancer Institute at Saint John's Health Center, Santa Monica (M.B.F., D.S.B.H.), and the Departments of Pathology (A.J.C.), Biomathematics (H.-J.W., D.A.E., R.M.E.), and Medicine (D.A.E.), University of California, Los Angeles - both in California; Melanoma Institute Australia and the University of Sydney, Sydney (J.F.T., O.E.N.), Peter MacCallum Cancer Centre, Melbourne, VIC (M.H.), Princess Alexandra Hospital, Brisbane, QLD (B.M.S.), and Newcastle Melanoma Unit, Waratah, NSW (P.H.) - all in Australia; Huntsman Cancer Institute, Salt Lake City (R.H.A., R.D.N.), and Intermountain Healthcare Cancer Services-Intermountain Medical Center, Murray (T.L.B.) - both in Utah; Istituto Nazionale dei Tumori Napoli, Naples (N.M.), Istituto Europeo di Oncologia, Milan (A.T.), and Istituto Oncologico Veneto-University of Padua, Padua (C.R.R.) - all in Italy; H. Lee Moffitt Cancer Center, Tampa, FL (J.S.Z.); Helsinki University Hospital, Helsinki (T.J.); Dallas Surgical Group, Dallas (P.D.B.); Universitair Medisch Centrum Groningen, Groningen (H.J.H.), and Netherlands Cancer Institute, Amsterdam (M.W.J.M.W.) - both in the Netherlands; Norfolk and Norwich University Hospital, Norwich (M. Moncrieff), and Guy's and St. Thomas' NHS Foundation Trust, London (A.M.-R.) - both in the United Kingdom; Swedish Melanoma Study Group-University Hospital Lund, Lund, Sweden (C.I.); University of Michigan, Ann Arbor (M.S.S.); Wake Forest University, Winston-Salem (E.A.L.), and Duke University, Durham (R.S.) - both in North Carolina; Ohio State University, Columbus (D.A.); University of Zurich, Zurich (R.D.), and Centre Hospitalier Universitaire Vaudois, Lausanne (M. Matter) - both in Switzerland; Penn State Hershey Cancer Institute, Hershey (R.I.N.), Thomas Jefferson University (A.C.B.) and Fox Chase Cancer Center (J.M.F.), Philadelphia, and St. Luke's University Health Network, Bethlehem (D.C.D.) - all in Pennsylvania; Greenville Health System Cancer Center, Greenville, SC (S.D.T.); Sunnybrook Research Institute, Toronto (F.W.), and Tom Baker Cancer Centre, Calgary, AB (G.M.) - both in Canada; University of Washington, Seattle (D.R.B.); Saint Louis University, St. Louis (E.H.); Vanderbilt University (D.B.J., M.C.K.), Nashville, and University of Tennessee, Knoxville (J.M.L.) - both in Tennessee; University Hospital Schleswig-Holstein-Campus Lübeck, Lübeck (P.T.), University Hospital of Würzburg, Würzburg (A.G.), and City Hospital of Nürnberg, Nuremberg (E.S.) - all in Germany; SUNY at Stony Brook Hospital Medical Center, Stony Brook (T.L.H.), Memorial Sloan Kettering Cancer Center, New York (C.E.A.), and Roswell Park Cancer Institute, Buffalo (J.M.K.) - all in New York; Northwestern University Feinberg School of Medicine (J.D.W.) and Rush University Medical Center (S.D.B.), Chicago; University of Wisconsin, Madison (H.B.N.); Tel Aviv Sourasky Medical Center, Tel Aviv, Israel (S.S.); M.D. Anderson Medical Center, Houston (J.E.G.); Johns Hopkins University School of Medicine, Baltimore (L.J.); University of Louisville, Louisville, KY (K.M.M.); Dartmouth-Hitchcock Medical Center, Lebanon, NH (R.J.B.); Hospital Clinic Barcelona, Barcelona (S.V.-S.); and Sentara CarePlex Hospital, Hampton, VA (R.A.H.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1613210DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548388PMC
June 2017

Guidelines for the use of platelet transfusions.

Br J Haematol 2017 02 23;176(3):365-394. Epub 2016 Dec 23.

NHSBT, Newcastle upon Tyne, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.14423DOI Listing
February 2017

Developing an e-learning resource for nurse airway assistants in the emergency department.

Br J Nurs 2017 Feb;26(4):217-221

Senior Lecturer, Centre for Medical Education, University of Dundee.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.12968/bjon.2017.26.4.217DOI Listing
February 2017

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma.

J Clin Oncol 2016 12 31;34(34):4102-4109. Epub 2016 Oct 31.

Adil I. Daud, University of California, San Francisco, San Francisco; Antoni Ribas, University of California, Los Angeles; Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles; Charlotte Roach and Grant Toland, Dako North America, Carpinteria, CA; Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Tara C. Gangadhar, Abramson Cancer Center at the University of Pennsylvania, Philadelphia; Hassane Zarour, University of Pittsburgh, Pittsburgh, PA; Roxana Dronca, Mayo Clinic, Rochester, MN; Jared K. Lunceford, Xiaoyun Nicole Li, Kenneth Emancipator, Marisa Dolled-Filhart, S. Peter Kang, and Scot Ebbinghaus, Merck & Co, Kenilworth, NJ; Caroline Robert, Gustave Roussy and Paris-Sud University, Villejuif, France; Anthony M. Joshua, Princess Margaret Cancer Centre, Toronto, ON, Canada; Richard Kefford, Crown Princess Mary Cancer Centre, Westmead Hospital and Melanoma Institute Australia; Richard Kefford, Macquarie University; and Richard Kefford and Peter Hersey, University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://ascopubs.org/doi/10.1200/JCO.2016.67.2477
Publisher Site
http://dx.doi.org/10.1200/JCO.2016.67.2477DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5562434PMC
December 2016

EZH2 as a mediator of treatment resistance in melanoma.

Pigment Cell Melanoma Res 2016 09 25;29(5):500-7. Epub 2016 May 25.

Melanoma Immunology and Oncology Group, The Centenary Institute, University of Sydney, Camperdown, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12481DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5021620PMC
September 2016

Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma.

J Immunother Cancer 2014 15;2. Epub 2014 Apr 15.

Discipline of Surgery, University of Adelaide, Adelaide Melanoma Unit, Royal Adelaide Hospital, Adelaide, South Australia Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/2051-1426-2-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4950896PMC
July 2016

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

J Clin Oncol 2016 05 7;34(13):1510-7. Epub 2016 Mar 7.

F. Stephen Hodi, Dana-Farber Cancer Institute, Boston, MA; Wen-Jen Hwu, The University of Texas MD Anderson Cancer Center, Houston; Amita Patnaik, South Texas Accelerated Research Therapeutics, San Antonio, TX; Richard Kefford, Westmead Hospital, Melanoma Institute Australia, and Macquarie University; Peter Hersey, University of Sydney, Sydney, Australia; Jeffrey S. Weber, H. Lee Moffitt Cancer Center, Tampa; Richard Joseph, Mayo Clinic, Jacksonville, FL; Adil Daud, University of California San Francisco, San Francisco; Omid Hamid, The Angeles Clinic and Research Institute; Antoni Ribas, University of California Los Angeles, Los Angeles, CA; Caroline Robert, Gustave-Roussy and Paris-Sud University, Villejuif-Paris-Sud, France; Tara C. Gangadhar, Abramson Cancer Center, Philadelphia, PA; Anthony M. Joshua, Princess Margaret Hospital, Toronto, Ontario, Canada; Roxana Dronca, Mayo Clinic, Rochester, MN; Darcy Hille, Dahai Xue, Xiaoyun Nicole Li, S. Peter Kang, Scot Ebbinghaus, and Andrea Perrone, Merck, Kenilworth, NJ; and Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.0391DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5070547PMC
May 2016

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB.

PLoS One 2015 6;10(4):e0123410. Epub 2015 Apr 6.

Melanoma Research, Kolling Institute of Medical Research, University of Sydney, Royal North Shore Hospital, St Leonards, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0123410PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4386825PMC
April 2016

Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma.

Neoplasia 2016 Feb;18(2):121-32

Systems Biology and Cancer Metabolism, Program for Quantitative Systems Biology, University of California Merced, Merced, CA 95343, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2016.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5005314PMC
February 2016

Acute Radiation Skin Toxicity Associated With BRAF Inhibitors.

J Clin Oncol 2016 Jan 27;34(3):e17-20. Epub 2014 May 27.

Crown Princess Mary Cancer Centre, Westmead Hospital, Westmead; The University of Sydney, Sydney, New South Wales, Australia

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.0565DOI Listing
January 2016

Side effects and toxicities of targeted therapies in stage IV melanoma.

Am J Ther 2015 Jan-Feb;22(1):44-53

1Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori-Fondazione G. Pascale, Naples, Italy; 2Odense University Hospital, Odense, Denmark; 3Newcastle University, Newcastle, Australia; 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina; 5Institut Gustave Roussy, Villejuif, France; 6University of Kiel, Kiel, Germany; 7Hospital La Paz, Madrid, Spain; and 8Institut Gustave Roussy, Villejuif, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0b013e3182a39858DOI Listing
September 2015

Melanoma early detection and awareness: how countries developing melanoma awareness programs could benefit from melanoma-proficient countries.

Am J Ther 2015 Jan-Feb;22(1):37-43

1Faculdade de Ciências Médicas, Minas Gerais, Brazil; 2Clinica Universitaria de Navarra, Pamplona, Spain; 3Odense University Hospital, Odense, Denmark; 4Instituto de Oncologia Angel Rolfo, Buenos Aires, Argentina; 5Blokhin Cancer Center, Moscow, Russia; 6Hospital Sainte Marguerite, Marseilles, France; 7Beijing Cancer Hospital, Beijing, China; 8Newcastle University, Newcastle, Australia; 9Hospital La Paz, Madrid, Spain; 10Sheba Medical Center, Tel Hashomer, Israel; 11Melanoma Advisory Board South Africa, Cape Town, South Africa; 12Princess Margaret Hospital, Toronto, Canada; 13University of Kiel, Kiel, Germany; 14M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MJT.0000000000000038DOI Listing
September 2015

Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma.

Future Oncol 2015 ;11(1):133-40

Kolling Medical Research Institute, Royal North Shore Hospital, University of Sydney, St Leonards, NSW 2065, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon.14.205DOI Listing
September 2015

Histone Modifications, Modifiers and Readers in Melanoma Resistance to Targeted and Immune Therapy.

Cancers (Basel) 2015 Sep 25;7(4):1959-82. Epub 2015 Sep 25.

Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown 2050, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers7040870DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695870PMC
September 2015

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients.

Clin Cancer Res 2015 Jul 21;21(14):3140-8. Epub 2015 Jan 21.

Melanoma Institute Australia, North Sydney, New South Wales, Australia. Sydney Medical School, the University of Sydney, Sydney, New South Wales, Australia. Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-2023DOI Listing
July 2015

Expression of the class 1 histone deacetylases HDAC8 and 3 are associated with improved survival of patients with metastatic melanoma.

Mod Pathol 2015 Jul 3;28(7):884-94. Epub 2015 Apr 3.

1] Melanoma Institute Australia, Sydney, New South Wales, Australia [2] Discipline of Medicine, Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia [3] Kolling Institute, Royal North Shore Hospital, The University of Sydney, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/modpathol201534
Publisher Site
http://dx.doi.org/10.1038/modpathol.2015.34DOI Listing
July 2015

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials.

Pigment Cell Melanoma Res 2015 May 22;28(3):245-53. Epub 2014 Dec 22.

Melanoma Institute Australia, Sydney, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/pcmr.12340
Publisher Site
http://dx.doi.org/10.1111/pcmr.12340DOI Listing
May 2015

Synergistic effects of MAPK and immune checkpoint inhibitors in melanoma: what is the best combination strategy?

Melanoma Manag 2015 Feb 25;2(1):15-19. Epub 2015 Feb 25.

Melanoma Institute Australia, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/mmt.14.26DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094588PMC
February 2015

EZH2: an emerging role in melanoma biology and strategies for targeted therapy.

Pigment Cell Melanoma Res 2015 Jan 27;28(1):21-30. Epub 2014 Jun 27.

Melanoma Research Group, Kolling Institute of Medical Research, University of Sydney, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12280DOI Listing
January 2015

The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

J Invest Dermatol 2014 Nov 6;134(11):2795-2805. Epub 2014 Jun 6.

Melanoma Research Group, Kolling Institute of Medical Research, University of Sydney, St Leonards, New South Wales, Australia; Melanoma Institute of Australia, North Sydney, New South Wales, Australia. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S0022202X153655
Publisher Site
http://dx.doi.org/10.1038/jid.2014.243DOI Listing
November 2014

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

Pigment Cell Melanoma Res 2014 Nov 3;27(6):1126-37. Epub 2014 Jul 3.

Melanoma Research Group, Kolling Institute of Medical Research, University of Sydney, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pcmr.12282DOI Listing
November 2014

How anti-PD1 treatments are changing the management of melanoma.

Melanoma Manag 2014 Nov 4;1(2):165-172. Epub 2014 Dec 4.

Melanoma Institute of Australia, Rocklands Road, North Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
https://www.futuremedicine.com/doi/10.2217/mmt.14.14
Publisher Site
http://dx.doi.org/10.2217/mmt.14.14DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6094707PMC
November 2014

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma.

Mol Oncol 2014 May 15;8(3):544-54. Epub 2014 Jan 15.

Westmead Institute for Cancer Research, University of Sydney at Westmead Millennium Institute, Westmead Hospital, Westmead, New South Wales 2145, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.molonc.2014.01.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5528644PMC
May 2014

Community experience of vemurafenib for BRAF(V600) melanoma.

Authors:
Peter Hersey

Lancet Oncol 2014 Apr 27;15(4):369-70. Epub 2014 Feb 27.

Kolling Institute, and Melanoma Institute of Australia, University of Sydney, NSW 2065, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(14)70079-8DOI Listing
April 2014

Regulators of global genome repair do not respond to DNA damaging therapy but correlate with survival in melanoma.

PLoS One 2013 5;8(8):e70424. Epub 2013 Aug 5.

School of Biomedical Sciences & Pharmacy, Faculty of Health, University of Newcastle, Australia and Hunter Medical Research Institute, Newcastle, NSW, Australia.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0070424PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3734271PMC
March 2014

Intralesional immunotherapy for melanoma.

J Surg Oncol 2014 Mar 3;109(4):320-6. Epub 2013 Dec 3.

Melanoma Institute Australia, North Sydney, NSW, Australia; Kolling Institute, The University of Sydney, St Leonards, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jso.23494DOI Listing
March 2014

Oncogenic activation of MEK/ERK primes melanoma cells for adaptation to endoplasmic reticulum stress.

J Invest Dermatol 2014 Feb 6;134(2):488-497. Epub 2013 Aug 6.

School of Medicine and Public Health, University of Newcastle, Callaghan, New South Wales, Australia. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/jid.2013.325DOI Listing
February 2014

A focus on PD-L1 in human melanoma.

Clin Cancer Res 2013 Feb 18;19(3):514-6. Epub 2012 Dec 18.

Kolling Institute, Royal North Shore Hospital & Melanoma Institute of Australia, University of Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-3312DOI Listing
February 2013

Lymphatic vessel density in primary melanomas predicts sentinel lymph node status and risk of metastasis.

Histopathology 2012 Oct;61(4):702-10

Ludwig Institute for Cancer Research, Parkville, Vic., AustraliaDepartment of Surgery, Royal Melbourne Hospital, University of Melbourne, Vic., AustraliaJack Brockhoff Reconstructive Plastic Surgery Research Unit, Royal Melbourne Hospital and Department of Anatomy, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Vic., AustraliaTumour Angiogenesis Program, Peter MacCallum Cancer Centre, East Melbourne, Vic., AustraliaTissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Camperdown, NSW, AustraliaThe University of Sydney, Sydney, NSW, AustraliaMelanoma Institute Australia, North Sydney, NSW, AustraliaThe Sir Peter MacCallum Department of Oncology, University of Melbourne, Vic., Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2559.2012.04310.xDOI Listing
October 2012

Combined targeted therapy and immunotherapy in the treatment of advanced melanoma.

Oncoimmunology 2012 Sep;1(6):997-999

Melanoma Institute Australia; Sydney, NSW Australia ; University of Sydney; Sydney, NSW Australia.

View Article

Download full-text PDF

Source
http://www.tandfonline.com/doi/abs/10.4161/onci.19865
Publisher Site
http://dx.doi.org/10.4161/onci.19865DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3489773PMC
September 2012

Evidence for upregulation of Bim and the splicing factor SRp55 in melanoma cells from patients treated with selective BRAF inhibitors.

Melanoma Res 2012 Jun;22(3):244-51

Oncology & Immunology Unit, Calvary Mater Newcastle Hospital, Royal North Shore Hospital, University of Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e328353eff2DOI Listing
June 2012

Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.

Clin Cancer Res 2012 Feb 15;18(3):783-95. Epub 2011 Dec 15.

The Centenary Institute, Newtown, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1166DOI Listing
February 2012

New challenges in endpoints for drug development in advanced melanoma.

Clin Cancer Res 2012 Jan 5;18(2):336-41. Epub 2011 Dec 5.

Department of Medicine, Division of Hematology-Oncology, University of California Los Angeles, CA90095, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-11-2323DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3422891PMC
January 2012

Update on melanoma and non-melanoma skin cancer. Annual Skin Cancer Conference 2011, Hamilton Island, Australia, 5–6 August 2011.

Expert Rev Anticancer Ther 2011 Dec;11(12):1829-32

Department of Dermatology, Medical University of Graz, Graz, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.11.180DOI Listing
December 2011

The emerging important role of microRNAs in the pathogenesis, diagnosis and treatment of human cancers.

Pathology 2011 Oct;43(6):657-71

Melanoma Institute Australia, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAT.0b013e32834a7358DOI Listing
October 2011

MicroRNA-149*, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma.

Proc Natl Acad Sci U S A 2011 Sep 6;108(38):15840-5. Epub 2011 Sep 6.

Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei 230027, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1019312108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3179083PMC
September 2011

Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein products.

J Biol Chem 2011 Aug 16;286(32):28181-91. Epub 2011 Jun 16.

Cancer Research Unit, School of Biomedical Sciences and Pharmacy, University of Newcastle, Callaghan, New South Wales 2308, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/jbc.M111.234419DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3151063PMC
August 2011

MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720.

Clin Cancer Res 2011 Feb 18;17(4):721-30. Epub 2010 Nov 18.

Immunology and Oncology Unit, Newcastle, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-2225DOI Listing
February 2011

TRAIL-induced apoptosis of human melanoma cells involves activation of caspase-4.

Apoptosis 2010 Oct;15(10):1211-22

Immunology and Oncology Unit, Newcastle Misericordiae Hospital, Room 443, David Maddison Clinical Sciences Building, Cnr. King and Watt Streets, Newcastle, NSW, 2300, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10495-010-0513-9DOI Listing
October 2010

Nucleotide excision repair gene expression after Cisplatin treatment in melanoma.

Cancer Res 2010 Oct 31;70(20):7918-26. Epub 2010 Aug 31.

Centre for Information Based Medicine, University of Newcastle, Newcastle, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-10-0161DOI Listing
October 2010

Biology and clinical applications of CD40 in cancer treatment.

Semin Oncol 2010 Oct;37(5):517-23

Division of Medical Oncology and Immunotherapy, Department of Oncology, University Hospital of Siena, Istituto Toscano Tumori, Siena, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminoncol.2010.09.002DOI Listing
October 2010

A randomized, double-blind, placebo-controlled study of high-dose bosentan in patients with stage IV metastatic melanoma receiving first-line dacarbazine chemotherapy.

Mol Cancer 2010 Mar 30;9:69. Epub 2010 Mar 30.

Westmead Institute for Cancer research and Melanoma Institute of Australia, University of Sydney at Westmead Hospital, NSW 2145, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1476-4598-9-69DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2856553PMC
March 2010

Immunotherapy of melanoma.

Authors:
Peter Hersey

Asia Pac J Clin Oncol 2010 Mar;6 Suppl 1:S2-8

Sydney and Newcastle Melanoma Units, Newcastle, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1743-7563.2010.01269.xDOI Listing
March 2010

Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.

Clin Cancer Res 2010 Feb 19;16(3):1042-8. Epub 2010 Jan 19.

University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-2033DOI Listing
February 2010

Lactate dehydrogenase 5 expression in melanoma increases with disease progression and is associated with expression of Bcl-XL and Mcl-1, but not Bcl-2 proteins.

Mod Pathol 2010 Jan 16;23(1):45-53. Epub 2009 Oct 16.

Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2009.129DOI Listing
January 2010

Treatment combinations targeting apoptosis to improve immunotherapy of melanoma.

Cancer Immunol Immunother 2009 Nov 24;58(11):1749-59. Epub 2009 Jun 24.

Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, Room 443, David Maddison Clinical Sciences Building, Cnr. King and Watt Streets, Newcastle, NSW 2300, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00262-009-0732-5DOI Listing
November 2009

Metabolic approaches to treatment of melanoma.

Clin Cancer Res 2009 Nov 27;15(21):6490-4. Epub 2009 Oct 27.

Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Newcastle, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-09-0251DOI Listing
November 2009

Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.

Neoplasia 2009 Sep;11(9):945-55

Immunology and Oncology Unit, Room 443, Calvary Mater Newcastle Hospital, NSW, Australia.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2735806PMC
http://dx.doi.org/10.1593/neo.09692DOI Listing
September 2009

Expression of glucose-regulated stress protein GRP78 is related to progression of melanoma.

Histopathology 2009 Mar;54(4):462-70

Department of Anatomical Pathology, Royal Prince Alfred Hospital, Sydney, NSW, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1365-2559.2009.03242.xDOI Listing
March 2009

Inhibition of MEK blocks GRP78 up-regulation and enhances apoptosis induced by ER stress in gastric cancer cells.

Cancer Lett 2009 Feb 1;274(1):40-6. Epub 2008 Oct 1.

Department Immunology, Anhui Medical University, PR China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2008.08.030DOI Listing
February 2009

Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human melanoma cells.

Carcinogenesis 2009 Feb 8;30(2):197-204. Epub 2008 Oct 8.

Immunology and Oncology Unit, Newcastle Misericordiae Hospital, David Maddison Clinical Sciences Building, Newcastle, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://carcin.oxfordjournals.org/content/30/2/197.full.pdf
Web Search
http://www.carcin.oxfordjournals.org/cgi/doi/10.1093/carcin/
Publisher Site
http://dx.doi.org/10.1093/carcin/bgn220DOI Listing
February 2009

Chemoablation of metastatic melanoma using intralesional Rose Bengal.

Melanoma Res 2008 Dec;18(6):405-11

Sydney Melanoma Unit, Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e32831328c7DOI Listing
December 2008

Involvement of endoplasmic reticulum stress in Docetaxel-induced JNK-dependent apoptosis of human melanoma.

Apoptosis 2008 Dec;13(12):1505-12

Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10495-008-0276-8DOI Listing
December 2008

Does the administration of mannitol prevent renal failure in open abdominal aortic aneurysm surgery?

Interact Cardiovasc Thorac Surg 2008 Oct 24;7(5):906-9. Epub 2008 Jul 24.

Department of Anaesthesia, Sunderland Royal Hospital, Sunderland, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1510/icvts.2008.184010DOI Listing
October 2008

Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress.

Cancer Res 2008 Aug;68(16):6708-17

Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-08-0349DOI Listing
August 2008

Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma.

Pigment Cell Melanoma Res 2008 Jun;21(3):358-67

Immunology and Oncology Unit, Calvary Mater Newcastle Hospital, Newcastle, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1755-148X.2008.00467.xDOI Listing
June 2008

Overcoming resistance to apoptosis in cancer therapy.

Adv Exp Med Biol 2008 ;615:105-26

Immunology and Oncology Unit, Newcastle Mater Hospital, Newcastle, NSW 2300, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-1-4020-6554-5_6DOI Listing
May 2008

Dramatic reduction of chronic lymphoedema of the lower limb with sorafenib therapy.

Melanoma Res 2008 Apr;18(2):161-2

Sydney Melanoma Unit, North Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CMR.0b013e3282f3d117DOI Listing
April 2008

Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.

Clin Cancer Res 2008 Mar 29;14(6):1659-68. Epub 2008 Feb 29.

Oncology and Immunology Unit, Calvary Mater Newcastle Hospital, University of Newcastle, Newcastle, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1422DOI Listing
March 2008